(TheNewswire)
LONDON, ONTARIO - TheNewswire- December 14, 2021 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage leader in regenerativemedicine and cell therapy therapeutics developing a potential‘functional cure’ for type 1 diabetes (T1D) and other chronicdiseases, is pleased to announce t oday it hasappointed executive Christopher Barnes as Vice President, InvestorRelations. Mr. Barnes will lead the execution of Sernova’s investorrelations strategy and communications activities.
New VP Investor Relations
Mr. Barnes has a track record of 2 3 years of experience in both investorrelations and capital markets. His previous investor relationsexperience includes being the investor relations head at a large NorthAmerican healthcare company. Additionally, he has worked in the c apital markets and institutional sales for three boutiqueinvestment dealers covering buy side accounts in Canada, the UnitedStates and Europe.
“We are pleased to welcome seasoned investorrelations and capital markets executive Christopher Barnes to theSernova management team,” commented Dr. Philip Toleikis, Presidentand CEO. “The ongoing success of our Cell Pouch System™ diabetesclinical program, rivalling our peers, and our evolving globalpharmaceutical partnering activities are catching the eye ofinstitutional investors and others. Christopher’s strong network ofrelationships across the North American investment community combinedwith his capital markets savvy and communications experience willaccelerate and broaden the awareness of Sernova’s prospects,developing the cell therapy industry’s most clinically successfulplatform to date, with our T1D study’s longest treated patient nowbeing insulin independent for over 20 months. He will work closely with our New York, US based LifeSciAdvisors team bolstering targeted investor outreach and other newinitiatives as well as support the shift in our shareholder base towards institutionalshareholders.”
Mr. Barnes’ appointment continues the buildout ofSernova’s management and internal clinical and regulatory, R&Dand corporate teams to support and continue the execution of theCompany’s growth plan.
Option and DSU Grants
In conjunction with team’s expansion and therecognition of Sernova’s significant accomplishments andtransformation over the last two years, the Sernova board of directorshas granted 13,575,484 stock options to certain officers, employeesand consultants of the Company, with each option being exercisableinto one common share at a price of $1.32 per share for a period of 5years, and granted 1,360,000 Deferred Share Units (DSU) to itsnon-management directors. The last company wide option and DSU grantsoccurred two years ago in 2019.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeuticsolutions using a medical device (Cell Pouch) and immune protectedtherapeutic cells / tissues (i.e. human donor cells, corrected humancells and stem cell-derived cells) to improve the treatment andquality of life of people with chronic metabolic diseases such asinsulin-dependent diabetes, blood disorders including hemophilia, andother diseases treated through cellular production of proteins orhormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
ABOUT SERNOVA’S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is anovel, proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device upon implantation is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins and hormones as required to treat disease.
The Cell Pouch, along with therapeutic cells, has beenshown to provide long-term safety and efficacy in small and largeanimal models of diabetes and has been proven to provide abiologically compatible environment for insulin-producing cells inhumans in a Canadian first-in-human study. Sernova is currentlyconducting a Phase I/II study at the University of Chicago. Positiveinitial results have been presented at several internationalscientific conferences.
FOR FURTHER INFORMATION, PLEASECONTACT:
Corey Davis, Ph.D.
LifeScience Advisors, LLC
Tel: 212-915-2577
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of thecompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management’s beliefs withrespect to future events and are based on information currentlyavailable to management on the date such statements were made. Manyfactors could cause Sernova’s actual results, performances orachievements to not be as anticipated, estimated or intended or todiffer materially from those expressed or implied by theforward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’squarterly and annual filings available on www.sedar.com for additionalinformation on risks and uncertainties relating to the forward-lookingstatements. Sernova expressly disclaims any intention or obligation toupdate or revise any forward-looking statements, whether as a resultof new information, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.